EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pulmonary Actinomycosis: A Hidden Threat with Clinical Impact

Raffaella Griffo iD, Jasmin K Jasuja, Benedikt Niedermaier iD, Sabine Wege, Janina Shala, Henrike Deissner iD, Lena Brendel, Romina M Rösch iD, Florian Eichhorn, Michael Allgäuer iD, Elizabeth Tong, Cosmas Wimmer und 3 weitere

Advances in Respiratory Medicine · 18.05.2026 · 94 (3) · 33

DOI: 10.3390/arm94030033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 18.05.2026. Verfasst von Raffaella Griffo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Thoraxklinik, Department of Thoracic Surgery, Heidelberg University Hospital, 69126 Heidelberg, Germany. Hauptthemen laut MEDLINE: Actinomycosis, Lung Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary actinomycosis is a rare chronic infection that frequently mimics lung malignancy, often leading to delayed diagnosis due to its non-specific clinical and radiological presentation. Given the diagnostic challenges associated with this condition, the aim of this study was to evaluate the clinical presentation, diagnostic pathways, treatment strategies, and outcomes of patients diagnosed with pulmonary actinomycosis in a single center.

Methods

We retrospectively reviewed patients diagnosed with pulmonary actinomycosis at our institution between January 2014 and December 2022. Diagnosis was established based on compatible clinical and radiological findings together with microbiological identification of Actinomyces by culture or polymerase chain reaction.

Results

Twenty-two patients were included in the final analysis. The median age was 61.5 years and males were more frequently affected (59%). The median time from initial hospitalization to definitive diagnosis was 70 days. Actinomyces odontolyticus was the most frequently identified species. All patients received antibiotic therapy, with a median treatment duration of 45.5 days. Thirteen patients underwent surgical intervention, performed either for diagnostic purposes or for treatment of complications. Complete disease eradication through surgical management was achieved in six cases. During follow-up (median 24 months), overall survival at three years was 78%, with one death directly related to pulmonary actinomycosis.

Conclusions

Pulmonary actinomycosis remains a diagnostic challenge due to its non-specific clinical presentation and low microbiological yield. Early clinical suspicion and a combined diagnostic approach including bronchoscopy and microbiological testing are essential for timely diagnosis. Surgical intervention may play an important diagnostic and therapeutic role in selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ActinomycosisLung DiseasesHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAnti-Bacterial AgentsActinomyces

Stichwörter der Autor:innen

diagnostic delaylung masspulmonary actinomycosisthoracic infectionthoracic surgery

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Thoraxklinik, Department of Thoracic Surgery, Heidelberg University Hospital, 69126 Heidelberg, Germany.
  • Department for Infectious Diseases, Heidelberg University Hospital, 69126 Heidelberg, Germany.
  • Institute for Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Division of Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Translation Lung Research Center (TLRC), German Center for Lung Research (DZL), 69120 Heidelberg, Germany.
  • Thoraxklinik, Department of Pneumology, Heidelberg University Hospital, 69126 Heidelberg, Germany.

ORCID-Profile: Raffaella Griffo, Benedikt Niedermaier, Henrike Deissner, Romina M Rösch, Michael Allgäuer, Hauke Winter

Zitieren

APA

Griffo, R., Jasuja, J. K., Niedermaier, B., Wege, S., Shala, J., Deissner, H., Brendel, L., Rösch, R. M., Eichhorn, F., Allgäuer, M., Tong, E., Wimmer, C., Eichhorn, M. E., Winter, H., & Klotz, L. V. (2026). Pulmonary Actinomycosis: A Hidden Threat with Clinical Impact. Advances in Respiratory Medicine, 94(3), 33. https://doi.org/10.3390/arm94030033

Vancouver

Griffo R, Jasuja JK, Niedermaier B, Wege S, Shala J, Deissner H, et al. Pulmonary Actinomycosis: A Hidden Threat with Clinical Impact. Advances in Respiratory Medicine. 2026;94(3):33. doi:10.3390/arm94030033

BibTeX
@article{Griffo2026,
  author = {Griffo, Raffaella and Jasuja, Jasmin K and Niedermaier, Benedikt and Wege, Sabine and Shala, Janina and Deissner, Henrike and Brendel, Lena and Rösch, Romina M and Eichhorn, Florian and Allgäuer, Michael and Tong, Elizabeth and Wimmer, Cosmas and Eichhorn, Martin E and Winter, Hauke and Klotz, Laura V},
  title = {Pulmonary Actinomycosis: A Hidden Threat with Clinical Impact},
  journal = {Advances in Respiratory Medicine},
  year = {2026},
  volume = {94},
  number = {3},
  pages = {33},
  doi = {10.3390/arm94030033}
}
Kostenlos starten →